Clarivate Epidemiology’s coverage of glomerulonephritis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate’s Pharma Industry Report provides pharma executives with a comprehensive summary of the current and future state of the global pharmaceutical industry. Scope This report pulls…
Epi Data Slicer
Epi Data Slicer
Epi Data Slicer
Epi Data Slicer
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key glioma patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of glioma for…
Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well…
In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast…
In 2020, sales of branded biologics for respiratory indications reached nearly $1.50 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-…
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
In 2020, sales of branded MAb biologics in oncology exceeded $30 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $3…
In 2020, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $4.18 billion in the major pharmaceutical markets under study (…